{
  "url": "https://openlegislation.uk/eu-regulation-2020-1182/annex",
  "json_url": "https://openlegislation.uk/eu-regulation-2020-1182/annex.json",
  "legislation": "eur/2020/1182",
  "legislation_title": "Commission Delegated Regulation (EU) 2020/1182 of 19 May 2020 amending, for the purposes of its adaptation to technical and scientific progress, Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2020-1182",
  "path": "annex",
  "kind": "annex",
  "number": null,
  "heading": null,
  "text": "In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:\n(1) the following entries are inserted:\nIndex No\nChemical name\nEC No\nCAS No\nClassification\nLabelling\nSpecific Conc. Limits, M-factors and ATE\nNotes\nHazard Class and Category Code(s)\nHazard statement Code(s)\nPictogram, Signal Word Code(s)\nHazard statement Code(s)\nSuppl. Hazard statement Code(s)\n‘007-030-00-3\nnitric acid …% [C ≤ 70 %]\n231-714-2\n7697-37-2.\nOx. Liq. 3\nAcute Tox. 3\nSkin Corr. 1A\nH272\nH331\nH314\nGHS03\nGHS06\nGHS05\nDgr\nH272\nH331\nH314\nEUH071\nOx. Liq. 3; H272: C ≥ 65 %\ninhalation: ATE = 2,65 mg/L (vapours)\nSkin Corr. 1A; H314: C ≥ 20 %\nSkin Corr. 1B; H314: 5 % ≤ C < 20 %\nB’\n‘014-048-00-5\nsilicon carbide fibres (with diameter < 3 μm, length > 5 μm and aspect ratio ≥ 3:1)\n206-991-8\n409-21-2\n308076-74-6\nCarc. 1B\nH350i\nGHS08\nDgr\nH350i’\n‘014-049-00-0\ntrimethoxyvinylsilane; trimethoxy(vinyl)silane\n220-449-8\n2768-02-7\nSkin Sens. 1B\nH317\nGHS07\nWng\nH317’\n‘014-050-00-6\ntris(2-methoxyethoxy)vinylsilane;\n6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane\n213-934-0\n1067-53-4\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD’\n‘016-098-00-3\ndimethyl disulphide\n210-871-0\n624-92-0\nFlam. Liq. 2\nAcute Tox. 3\nAcute Tox. 3\nSTOT SE 3\nSTOT SE 1\nEye Irrit. 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH225\nH331\nH301\nH336\nH370 (upper respiratory tract, inhalation)\nH319\nH317\nH400\nH410\nGHS02\nGHS06\nGHS08\nGHS09\nDgr\nH225\nH331\nH301\nH336\nH370 (upper respiratory tract, inhalation)\nH319\nH317\nH410\ninhalation: ATE = 5 mg/L (vapours)\noral: ATE = 190 mg/kg bw\nM = 1\nM = 10’\n‘029-024-00-X\ngranulated copper;\n[particle length: from 0,9 mm to 6,0 mm; particle width: from 0,494 to 0,949 mm]\n231-159-6\n7440-50-8\nAquatic Chronic 2\nH411\nGHS09\nH411’\n‘029-025-00-5\nbis(N-hydroxy-N-nitrosocyclohexylaminato-O,O’)copper;\nbis(N-cyclohexyl-diazenium-dioxy)-copper;\n[Cu-HDO]\n239-703-4\n312600-89-8\n15627-09-5\nFlam. Sol. 1\nAcute Tox. 4\nSTOT RE 2\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH228\nH302\nH373 (liver)\nH318\nH400\nH410\nGHS02\nGHS07\nGHS08\nGHS05\nGHS09\nDgr\nH228\nH302\nH373(liver)\nH318\nH410\noral: ATE = 360 mg/kg bw\nM = 1\nM = 1’\n‘050-031-00-9\ndioctyltin dilaurate; [1]\nstannane, dioctyl-, bis(coco acyloxy) derivs. [2]\n222-883-3 [1] 293-901-5 [2]\n3648-18-8 [1] 91648-39-4 [2]\nRepr. 1B\nSTOT RE 1\nH360D\nH372 (immune system)\nGHS08\nDgr\nH360D\nH372 (immune system)’\n‘601-092-00-0\ndibenzo[def,p]chrysene;\ndibenzo[a,l]pyrene\n205-886-4\n191-30-0\nCarc. 1B\nMuta. 2\nH350\nH341\nGHS08\nDgr\nH350\nH341\nCarc. 1B; H350: C ≥ 0,001 %’\n‘603-237-00-3\nipconazole (ISO);\n(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorobenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol\n-\n125225-28-7\n115850-69-6\n115937-89-8\nRepr. 1B\nAcute Tox. 4\nSTOT RE 2\nAquatic Chronic 1\nH360D\nH302\nH373 (eyes, skin, liver)\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH360D\nH302\nH373 (eyes, skin, liver)\nH410\noral: ATE = 500 mg/kg bw\nM = 100’\n‘603-238-00-9\nbis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme\n205-594-7\n143-24-8\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD’\n‘603-239-00-4\npaclobutrazol (ISO);\n(2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol\n-\n76738-62-0\nRepr. 2\nAcute Tox. 4\nAcute Tox. 4\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH361d\nH332\nH302\nH319\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361d\nH332\nH302\nH319\nH410\ninhalation: ATE = 3,13 mg/L (dusts or mists)\noral: ATE = 490 mg/kg bw\nM = 10\nM = 10’\n‘603-240-00-X\n2,2-bis(bromomethyl)propane-1,3-diol\n221-967-7\n3296-90-0\nCarc. 1B\nMuta. 1B\nH350\nH340\nGHS08\nDgr\nH350\nH340’\n‘603-241-00-5\ngeraniol;\n(2E)-3,7-dimethylocta-2,6-dien-1-ol\n203-377-1\n106-24-1\nSkin Sens. 1\nH317\nGHS07\nWng\nH317’\n‘605-041-00-3\n2-(4-tert-butylbenzyl)propionaldehyde\n201-289-8\n80-54-6\nRepr. 1B\nH360Fd\nGHS08\nDgr\nH360Fd’\n‘607-738-00-8\nMCPA-thioethyl (ISO);\nS-ethyl (4-chloro-2-methylphenoxy)ethanethioate; S-ethyl 4-chloro-o-tolyloxythioacetate\n246-831-4\n25319-90-8\nAcute Tox. 4\nSTOT RE. 2\nAquatic Acute 1 Aquatic Chronic 1\nH302\nH373 (liver)\nH400\nH410\nGHS07\nGHS08\nGHS09\nWng\nH302\nH373 (liver)\nH410\noral: ATE = 450 mg/kg bw\nM = 10\nM = 10’\n‘607-740-00-9\ndiisooctyl phthalate\n248-523-5\n27554-26-3\nRepr. 1B\nH360FD\nGHS08\nDgr\nH360FD’\n‘607-741-00-4\n4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one; flupyradifurone\n-\n951659-40-8\nAcute Tox. 4\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH373 (muscle)\nH400\nH410\nGHS07\nGHS08\nGHS09\nWng\nH302\nH373 (muscle)\nH410\noral: ATE = 500 mg/kg bw\nM = 10\nM = 10’\n‘607-742-00-X\nthiencarbazone-methyl (ISO);\nmethyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5- methylthiophene-3-carboxylate\n-\n317815-83-1\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 1000\nM = 1000’\n‘607-743-00-5\nL-(+)-lactic acid;\n(2S)-2-hydroxypropanoic acid\n201-196-2\n79-33-4\nSkin Corr. 1C\nEye Dam. 1\nH314\nH318\nGHS05\nDgr\nH314\nEUH071’\n‘607-744-00-0\n2-methoxyethyl acrylate\n221-499-3\n3121-61-7\nFlam. Liq. 3\nMuta. 2\nRepr. 1B\nAcute Tox. 3\nAcute Tox. 4\nSkin Corr. 1C\nEye Dam. 1\nSkin Sens. 1\nH226\nH341\nH360FD\nH331\nH302\nH314\nH318\nH317\nGHS02\nGHS05\nGHS06\nGHS08\nDgr\nH226\nH341\nH360FD\nH331\nH302\nH314\nH317\nEUH071\ninhalation: ATE = 2,7 mg/L (vapours)\noral: ATE = 404 mg/kg bw’\n‘607-745-00-6\nglyoxylic acid …%\n206-058-5\n298-12-4\nEye Dam. 1\nSkin Sens. 1B\nH318\nH317\nGHS05\nGHS07\nDgr\nH318\nH317\nB’\n‘607-746-00-1\nsodium N-(hydroxymethyl)glycinate;\n[formaldehyde released from sodium N-(hydroxymethyl)glycinate]\n274-357-8\n70161-44-3\nCarc. 1B\nMuta. 2\nAcute Tox. 4\nAcute Tox. 4\nSTOT SE 3\nSkin Irrit. 2\nEye Irrit. 2\nSkin Sens. 1\nH350\nH341\nH332\nH302\nH335\nH315\nH319\nH317\nGHS08\nGHS07\nDgr\nH350\nH341\nH332\nH302\nH335\nH315\nH319\nH317\ninhalation: ATE = 3 mg/L (dusts or mists)\noral: ATE = 1100 mg/kg bw\n8\n9’\n‘611-181-00-6\npotassium (oxido-NNO-azoxy)cyclohexane;\ncyclohexylhydroxydiazene 1-oxide, potassium salt;\n[K-HDO]\n-\n66603-10-9\nFlam. Sol. 1\nAcute Tox. 3\nSTOT RE 2\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 2\nH228\nH301\nH373 (liver)\nH315\nH318\nH411\nGHS02\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH228\nH301\nH373 (liver)\nH315\nH318\nH411\noral: ATE = 136 mg/kg bw’\n‘612-294-00-3\nmecetronium etilsulfate;\nN-ethyl-N,N-dimethylhexadecan-1-aminium ethyl sulfate;\nmecetronium ethyl sulphate;\n[MES]\n221-106-5\n3006-10-8\nSkin Corr. 1\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH314\nH410\nEUH071\nM = 100\nM = 1000’\n‘613-331-00-6\n(2RS)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol;\nmefentrifluconazole\n-\n1417782-03-6\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\nM = 1\nM = 1’\n‘613-332-00-1\noxathiapiprolin (ISO);\n1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone\n-\n1003318-67-9\nAquatic Chronic 1\nH410\nGHS09\nWng\nH410\nM = 1’\n‘613-333-00-7\npyrithione zinc; (T-4)-bis[1-(hydroxy-.kappa.O)pyridine-2(1H)-thionato-.kappa.S]zinc\n236-671-3\n13463-41-7\nRepr. 1B\nAcute Tox. 2\nAcute Tox. 3\nSTOT RE 1\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH360D\nH330\nH301\nH372\nH318\nH400\nH410\nGHS08\nGHS06\nGHS05\nGHS09\nDgr\nH360D\nH330\nH301\nH372\nH318\nH410\ninhalation: ATE = 0,14 mg/L (dusts or mists)\noral: ATE = 221 mg/kg bw\nM = 1000\nM = 10’\n‘613-334-00-2\nflurochloridone (ISO);\n3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one\n262-661-3\n61213-25-0\nRepr. 1B\nAcute Tox. 4\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH360FD\nH302\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH360FD\nH302\nH317\nH410\noral: ATE = 500 mg/kg bw\nM = 100\nM = 100’\n‘613-335-00-8\n4,5-dichloro-2-octyl-2H-isothiazol-3-one; [DCOIT]\n264-843-8\n64359-81-5\nAcute Tox. 2\nAcute Tox. 4\nSkin Corr. 1\nEye Dam. 1\nSkin Sens. 1A\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH302\nH314\nH318\nH317\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH330\nH302\nH314\nH317\nH410\nEUH071\ninhalation: ATE = 0,16 mg/L (dusts or mists)\noral: ATE = 567 mg/kg bw\nSkin Irrit. 2; H315: 0,025 % ≤ C < 5 %\nEye Irrit. 2; H319: 0,025 % ≤ C < 3 %\nSkin Sens. 1A; H317: C ≥ 0,0015 %\nM = 100\nM = 100’\n‘613-336-00-3\n2-methyl-1,2-benzothiazol-3(2H)-one;\n[MBIT]\n-\n2527-66-4\nAcute Tox. 4\nAcute Tox. 3\nSkin Corr. 1C\nEye Dam. 1\nSkin Sens. 1A\nAquatic Acute 1\nAquatic Chronic 2\nH312\nH301\nH314\nH318\nH317\nH400\nH411\nGHS06\nGHS05\nGHS09\nDgr\nH312\nH301\nH314\nH317\nH410\nEUH071\ndermal: ATE = 1100 mg/kg bw\noral: ATE = 175 mg/kg bw\nSkin Sens. 1A; H317: C ≥ 0,0015 %\nM = 1’\n‘616-228-00-4\n3-(difluoromethyl)-1-methyl-N-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide;\nfluxapyroxad\n-\n907204-31-3\nLact.\nAquatic Acute 1\nAquatic Chronic 1\nH362\nH400\nH410\nGHS09\nWng\nH362\nH410\nM = 1\nM = 1’\n‘616-230-00-5\nN-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA]\n213-103-2\n924-42-5\nCarc. 1B\nMuta. 1B\nSTOT RE 1\nH350\nH340\nH372 (peripheral nervous system)\nGHS08\nDgr\nH350\nH340\nH372 (peripheral nervous system)’\n‘616-231-00-0\n5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]-1H-pyrazole-4-carboxamide; 2'-[(RS)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide;\npenflufen\n-\n494793-67-8\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\nM = 1\nM = 1’\n‘616-232-00-6\niprovalicarb (ISO);\nisopropyl [(2S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate\n-\n140923-17-7\nCarc. 2\nH351\nGHS08\nWng\nH351’\n‘616-233-00-1\nsilthiofam (ISO);\nN-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide\n-\n175217-20-6\nSTOT RE 2\nAquatic Chronic 2\nH373\nH411\nGHS08\nGHS09\nWng\nH373\nH411’\n‘650-057-00-6\nMargosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide]\n283-644-7\n84696-25-3\nAquatic Chronic 3\nH412\nH412’\n(2) the entries corresponding to index numbers 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616-014-00-0 and 617-006-00-X are replaced by the following entries respectively:\nIndex No\nChemical name\nEC No\nCAS No\nClassification\nLabelling\nSpecific Conc. Limits, M-factors and ATE\nNotes\nHazard Class and Category Code(s)\nHazard statement Code(s)\nPictogram, Signal Word Code(s)\nHazard statement Code(s)\nSuppl. Hazard statement Code(s)\n‘007-004-00-1\nnitric acid …% [C > 70 %]\n231-714-2\n7697-37-2\nOx. Liq. 2\nAcute Tox. 1\nSkin Corr. 1A\nH272\nH330\nH314\nGHS03\nGHS06\nGHS05\nDgr\nH272\nH330\nH314\nEUH071\nOx. Liq. 2; H272: C ≥ 99 %\nOx. Liq. 3; H272: 70 % ≤ C < 99 %\nB’\n‘014-018-00-1\noctamethylcyclotetrasiloxane;\n[D4]\n209-136-7\n556-67-2\nRepr. 2\nAquatic Chronic 1\nH361f ***\nH410\nGHS08\nGHS09\nWng\nH361f ***\nH410\nM = 10’\n‘015-134-00-5\npirimiphos-methyl (ISO);\nO-[2-(diethylamino)-6-methylpyrimidin-4-yl] O,O-dimethyl phosphorothioate\n249-528-5\n29232-93-7\nAcute Tox. 4\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH302\nH372 (nervous system)\nH400\nH410\nGHS07\nGHS08\nGHS09\nDgr\nH302\nH372 (nervous system)\nH410\noral: ATE = 1414 mg/kg bw\nM = 1000\nM = 1000’\n‘015-181-00-1\nphosphine\n232-260-8\n7803-51-2\nFlam. Gas 1\nPress. Gas\nAcute Tox. 1\nSkin Corr. 1B\nAquatic Acute 1\nH220\nH330\nH314\nH400\nGHS02\nGHS04\nGHS06\nGHS05\nGHS09\nDgr\nH220\nH330\nH314\nH400\ninhalation:\nATE = 10 ppmV (gases)\nU’\n‘050-021-00-4\ndichlorodioctylstannane\n222-583-2\n3542-36-7\nRepr. 1B\nAcute Tox. 2\nSTOT RE 1\nAquatic Chronic 3\nH360D\nH330\nH372 **\nH412\nGHS08\nGHS06\nDgr\nH360D\nH330\nH372 **\nH412\nRepr. 1B; H360 D: C ≥ 0,03 %\ninhalation: ATE = 0,098 mg/L (dusts or mists)’\n‘050-027-00-7\n2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE]\n239-622-4\n15571-58-1\nRepr. 1B\nSTOT RE 1\nAquatic Acute 1\nAquatic Chronic 1\nH360D\nH372 (immune system)\nH400\nH410\nGHS08\nGHS09\nDgr\nH360D\nH372 (immune system)\nH410’\n‘082-013-00-1\nlead powder; [particle diameter < 1 mm]\n231-100-4\n7439-92-1\nRepr. 1A\nLact.\nAquatic Acute 1\nAquatic Chronic 1\nH360FD\nH362\nH400\nH410\nGHS08\nGHS09\nDgr\nH360FD H362\nH410\nRepr. 1A; H360D: C ≥ 0,03 %\nM = 1\nM = 10’\n‘603-014-00-0\n2-butoxyethanol;\nethylene glycol monobutyl ether\n203-905-0\n111-76-2\nAcute Tox. 4*\nAcute Tox. 4\nSkin Irrit. 2\nEye Irrit. 2\nH332\nH302\nH315\nH319\nGHS07\nWng\nH332\nH302\nH315\nH319\noral: ATE = 1200 mg/kg bw’\n‘603-065-00-9\nm-bis(2,3-epoxypropoxy)benzene;\nresorcinol diglycidyl ether\n202-987-5\n101-90-6\nCarc. 1B\nMuta. 2\nAcute Tox. 3\nAcute Tox. 4\nSkin Irrit. 2\nEye Irrit. 2\nSkin Sens. 1\nAquatic Chronic 3\nH350\nH341\nH311\nH302\nH315\nH319\nH317\nH412\nGHS08\nGHS06\nDgr\nH350\nH341\nH311\nH302\nH315\nH319\nH317\nH412\ndermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw’\n‘607-177-00-9\ntribenuron-methyl (ISO);\nmethyl 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylcarbamoylsulfamoyl]benzoate\n401-190-1\n101200-48-0\nSTOT RE 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH373\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH373\nH317\nH410\nM = 100\nM = 100’\n‘607-256-00-8\nazoxystrobin (ISO);\nmethyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate\n-\n131860-33-8\nAcute Tox. 3\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH400\nH410\nGHS06\nGHS09\nDgr\nH331\nH410\ninhalation:\nATE = 0,7 mg/L (dusts or mists)\nM = 10\nM = 10’\n‘607-314-00-2\nethofumesate (ISO);\n(RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate\n247-525-3\n26225-79-6\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 1\nM = 1’\n‘609-041-00-4\n2,4-dinitrophenol\n200-087-7\n51-28-5\nAcute Tox. 3 *\nAcute Tox. 3\nAcute Tox. 2\nSTOT RE 1\nAquatic Acute 1\nH331\nH311\nH300\nH372\nH400\nGHS06\nGHS08\nGHS09\nDgr\nH331\nH311\nH300\nH372\nH400\ndermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw’\n‘609-064-00-X\nmesotrione (ISO);\n2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione\n-\n104206-82-8\nRepr. 2\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH361d\nH373 (eyes, nervous system)\nH400\nH410\nGHS08\nGHS09\nWng\nH361d\nH373 (eyes, nervous system)\nH410\nM = 10\nM = 10’\n‘613-112-00-5\nocthilinone (ISO);\n2-octyl-2H-isothiazol-3-one; [OIT]\n247-761-7\n26530-20-1\nAcute Tox. 2\nAcute Tox. 3\nAcute Tox. 3\nSkin Corr. 1\nEye Dam. 1\nSkin Sens. 1A\nAquatic Acute 1 Aquatic Chronic 1\nH330\nH311\nH301\nH314\nH318\nH317\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH330\nH311\nH301\nH314\nH317\nH410\nEUH071\ninhalation: ATE = 0,27 mg/L (dusts or mists)\ndermal: ATE = 311 mg/kg bw oral: ATE = 125 mg/kg bw\nSkin Sens. 1A; H317: C ≥ 0,0015 %\nM = 100\nM = 100’\n‘613-115-00-1\nhymexazol (ISO);\n3-hydroxy-5-methylisoxazole\n233-000-6\n10004-44-1\nRepr. 2\nAcute Tox. 4\nEye Dam. 1\nSkin Sens. 1\nAquatic Chronic 2\nH361d\nH302\nH318\nH317\nH411\nGHS08\nGHS07\nGHS05\nGHS09\nDgr\nH361d\nH302\nH318\nH317\nH411\noral: ATE = 1600 mg/kg bw’\n‘613-125-00-6\nhexythiazox (ISO);\ntrans-5-(4-chlorophenyl)-N-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide\n-\n78587-05-0\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 1\nM = 1’\n‘613-202-00-4\npymetrozine (ISO);\n(E)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one\n-\n123312-89-0\nCarc. 2\nRepr. 2\nAquatic Chronic 1\nH351\nH361fd\nH410\nGHS08\nGHS09\nWng\nH351\nH361fd\nH410\nM = 1’\n‘613-259-00-5\nimiprothrin (ISO);\nreaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate\n428-790-6\n72963-72-5\nCarc. 2\nAcute Tox. 4\nAcute Tox. 4\nSTOT SE 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH332\nH302\nH371 (nervous system; oral, inhalation)\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH332\nH302\nH371 (nervous system; oral, inhalation)\nH410\ninhalation: ATE = 1,4 mg/L (dusts or mists)\noral: ATE = 550 mg/kg bw\nM = 10\nM = 10’\n‘616-014-00-0\nbutanone oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime\n202-496-6\n96-29-7\nCarc. 1B\nAcute Tox. 4\nAcute Tox. 3\nSTOT SE 3\nSTOT SE 1\nSTOT RE 2\nSkin Irrit. 2\nEye Dam. 1\nSkin Sens. 1\nH350\nH312\nH301\nH336\nH370 (upper respiratory tract)\nH373 (blood system)\nH315\nH318\nH317\nGHS08\nGHS06\nGHS05\nDgr\nH350\nH312\nH301\nH336\nH370 (upper respiratory tract)\nH373 (blood system)\nH315\nH318\nH317\ndermal: ATE = 1100 mg/kg bw oral: ATE = 100 mg/kg bw’\n‘617-006-00-X\nbis(α,α-dimethylbenzyl) peroxide\n201-279-3\n80-43-3\nOrg. Perox. F\nRepr. 1B\nSkin Irrit. 2\nEye Irrit. 2\nAquatic Chronic 2\nH242\nH360D\nH315\nH319\nH411\nGHS02\nGHS08\nGHS07\nGHS09\nDgr\nH242\nH360D\nH315\nH319\nH411’\n(3) the entries corresponding to index numbers 601-064-00-8 and 607-693-00-4 are deleted.",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2020/1182/annex",
    "retrieved_at": "2026-11-01T14:42:29.340956+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}